EUVIMEDEUVIMED entdecken
Crossref

Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR

Alice Laschuk Herlinger, Gustavo Lovatto Michaelsen, Marialva Sinigaglia, Lívia Fratini, Gabriela Nogueira Debom, Elizandra Braganhol, Caroline Brunetto de Farias, Algemir Lunardi Brunetto, André Tesainer Brunetto, Mariane da Cunha Jaeger, Rafael Roesler

NeuroMolecular Medicine · 2023

DOI: 10.1007/s12017-023-08758-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift NeuroMolecular Medicine, 2023. Verfasst von Alice Laschuk Herlinger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre…. Hauptthemen laut MEDLINE: Medulloblastoma, Antineoplastic Agents, Brain Neoplasms, Cerebellar Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Hospital de Clínicas de Porto Alegre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medulloblastoma (MB) is a heterogeneous group of malignant pediatric brain tumors, divided into molecular groups with distinct biological features and prognoses. Currently available therapy often results in poor long-term quality of life for patients, which will be afflicted by neurological, neuropsychiatric, and emotional sequelae. Identifying novel therapeutic agents capable of targeting the tumors without jeopardizing patients' quality of life is imperative. Rosmarinic acid (RA) is a plant-derived compound whose action against a series of diseases including cancer has been investigated, with no side effects reported so far. Previous studies have not examined whether RA has effects in MB. Here, we show RA is cytotoxic against human Daoy (IC50 = 168 μM) and D283 (IC50 = 334 μM) MB cells. Exposure to RA for 48 h reduced histone deacetylase 1 (HDAC1) expression while increasing H3K9 hyperacetylation, reduced epidermal growth factor (EGFR) expression, and inhibited EGFR downstream targets extracellular-regulated kinase (ERK)1/2 and AKT in Daoy cells. These modifications were accompanied by increased expression of CDKN1A/p21, reduced expression of SOX2, and a decrease in proliferative rate. Treatment with RA also reduced cancer stem cell markers expression and neurosphere size. Taken together, our findings indicate that RA can reduce cell proliferation and stemness and induce cell cycle arrest in MB cells. Mechanisms mediating these effects may include targeting HDAC1, EGFR, and ERK signaling, and promoting p21 expression, possibly through an increase in H3K9ac and AKT deactivation. RA should be further investigated as a potential anticancer agent in experimental MB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaAntineoplastic AgentsBrain NeoplasmsCerebellar NeoplasmsHumansChildEpidermal Growth FactorProto-Oncogene Proteins c-aktQuality of LifeCell ProliferationErbB ReceptorsCell Line, Tumor

Stichwörter der Autor:innen

Brain tumorEpidermal growth factor receptorHistone deacetylase inhibitorMedulloblastomaRosmarinic acidStem cell-like phenotype

Substanzen

Epidermal Growth FactorProto-Oncogene Proteins c-aktAntineoplastic AgentsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil. aherlinger@hcpa.edu.br.
  • National Science and Technology Institute for Children's Cancer Biology and Pediatric Oncology - INCT BioOncoPed, Porto Alegre, RS, 90035-003, Brazil. aherlinger@hcpa.edu.br.
  • Graduate Program in Bioinformatics, Digital Metropolis Institute, Federal University of Rio Grande do Norte, Natal, RN, 59078-400, Brazil.
  • Children's Cancer Institute, Porto Alegre, RS, 90620-110, Brazil.
  • Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
  • National Science and Technology Institute for Children's Cancer Biology and Pediatric Oncology - INCT BioOncoPed, Porto Alegre, RS, 90035-003, Brazil.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Hospital de Clínicas de Porto Alegre

Zitieren

APA

Laschuk Herlinger, A., Lovatto Michaelsen, G., Sinigaglia, M., Fratini, L., Nogueira Debom, G., Braganhol, E., Brunetto de Farias, C., Lunardi Brunetto, A., Tesainer Brunetto, A., da Cunha Jaeger, M., & Roesler, R. (2023). Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR. NeuroMolecular Medicine. https://doi.org/10.1007/s12017-023-08758-x

Vancouver

Laschuk Herlinger A, Lovatto Michaelsen G, Sinigaglia M, Fratini L, Nogueira Debom G, Braganhol E, et al. Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR. NeuroMolecular Medicine. 2023. doi:10.1007/s12017-023-08758-x

BibTeX
@article{LaschukHerlinger2023,
  author = {Laschuk Herlinger, Alice and Lovatto Michaelsen, Gustavo and Sinigaglia, Marialva and Fratini, Lívia and Nogueira Debom, Gabriela and Braganhol, Elizandra and Brunetto de Farias, Caroline and Lunardi Brunetto, Algemir and Tesainer Brunetto, André and da Cunha Jaeger, Mariane and Roesler, Rafael},
  title = {Modulation of Viability, Proliferation, and Stemness by Rosmarinic Acid in Medulloblastoma Cells: Involvement of HDACs and EGFR},
  journal = {NeuroMolecular Medicine},
  year = {2023},
  doi = {10.1007/s12017-023-08758-x}
}
Kostenlos starten →